Who
John B. Moriarty
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Kardigan; Chief Legal Officer, Avidity Biosciences; Chief Legal Officer, Mirati Therapeutics; EVP, Ch. Legal Officer & Sec., Olema Pharmaceuticals; EVP, General Counsel, Portola Pharmaceuticals; EVP & General Counsel, Alexion Pharmaceuticals.
In numbers
- Trades disclosed
- 110
- Buys
- 0
- Sells
- 27
- Bought
- $0
- Sold
- $10.2M
- Companies
- 6
- Companies where not an officer
- 0
- First trade
- 10 Dec 2012
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | KARD KardiganBiotechnology | SEC FORM 4 Code A | —47,784 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | KARD KardiganBiotechnology | SEC FORM 4 Code A | —47,784 at $0.00 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —92,054 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —160,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —160,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciences | SEC FORM 4 Code D | —92,054 | filing |
| 7 Jan 2026filed 9 Jan 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Sold | $171K2,374 at $72.23 | filing |
| 7 Jan 2026filed 9 Jan 2026 | Avidity Biosciences | SEC FORM 4 Sold | $171K2,374 at $72.23 | filing |
| 17 Dec 2025filed 19 Dec 2025 | Avidity Biosciences | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | Avidity Biosciences | SEC FORM 4 Code F | $1.9M26,824 at $71.87 | filing |
| 4 Aug 2025filed 5 Aug 2025 | Avidity Biosciences | SEC FORM 4 Sold | $81K2,245 at $36.21 | filing |
| 6 Jan 2025filed 8 Jan 2025 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Jan 2025filed 8 Jan 2025 | Avidity Biosciences | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Avidity Biosciences | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code D | —83,525 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code D | —675 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code D | —71,660 | filing |
News
No headline names them, or the companies they trade most, lately.